Page 150 - Genomic Testing News Today

A study highlights an unmet need for patients with acute myeloid leukemia (AML) to access and afford genomic testing, especially among an older patient population.

Coverage of sessions on disparities in access to clinical trials and cancer screening, as well as relationships each to outcomes. A joint session presented by ASCO and the European Society for Medical Oncology (ESMO) highlighted progress and lingering gaps in lung and colorectal screening.

The UK’s first fully automated system for clinical cancer genomic testing is to be established in a partnership between laboratory automation specialists Automata and The Royal Marsden NHS Foundation Trust.

Cancer genome testing has revolutionized the field of cancer care.

Mark A. Socinski, MD, executive director at AdventHealth Cancer Institute, shares insight on the cost-effectiveness and utility of biomarker testing in non–small cell lung cancer (NSCLC).

On this episode of Managed Care Cast, we feature several leaders in diversity, equity, and inclusion advancing health equity in their respective organization’s policy and practice initiatives.

/PRNewswire/ -- The "Digital PCR (dPCR) and Real-time PCR (qPCR) Market by Product (Instruments, Reagents & Consumables, Software & Services), Application...

Mike Lattanzi, MD, genitourinary medical oncologist, Texas Oncology, discusses the importance of keeping pace with precision oncology options as rates for prostate cancer increase.

Bangalore (Karnataka) [India], April 6 (ANI/PNN): Jain (Deemed-to-be University) recently launched two top courses in the study of sciences:

China, theyve posted 412 in the past six months. that means that or it seems to mean there are things happening in china that we dont know about. the thats the worry. the unknown, really, is the worry. jessica? >> absolutely. we know that the response from the u.s. and some much these other countries has been to implement these new testing requirements. is there any indication of how effective this is going to be? >> reporter: it is not fool proof. the hope here is at the very least with genomic...